It works by preventing or treating malaria, a red blood cell infection transmitted by the bite of a mosquito. However, this medicine is not used to treat severe or complicated malaria. Hydroxychloroquine should you take if you are anemic Do you have to be weaned off of plaquenil The Global Hydroxychloroquine Sulfate Market research report offers in-depth analysis of the data collected including the summary of the present scenario of the global “Hydroxychloroquine Sulfate Market“. The research report assists the market players while taking an important decision that leads to development and growth of the Hydroxychloroquine Sulfate market. Being a manufacturer of API makes Mylan one of the few global generics companies with a comprehensive, vertically integrated supply chain. This provides us with an extra measure in the quality process that we can own, and it also helps us maintain deep insight into diverse markets and therapeutic segments. Mylan is a global healthcare company focused on making high quality medicines available to everyone who needs them. We offer a robust portfolio of more than 7,500 products, including biosimilars, generics, brand, and over-the-counter remedies. It is also used to treat acute and chronic rheumatoid arthritis. Hydroxychloroquine is used to treat discoid lupus erythematosus (DLE) or systemic lupus erythematosus (SLE or lupus). Hydroxychloroquine mfg by mylan Mylan-Hydroxychloroquine - Rexall, API Manufacturing Mylan Chloroquine phosphate tablets in hindiRetinal toxicity of hydroxychloroquine Mylan manufactures HYDROXYCHLOROQUINE SULFATE Tablets, USP Plaquenil in strengths of 200 mg Product Profile - Mylan. Product Catalog -. Product Profile -. Several drug companies currently manufacture generic Plaquenil hydroxychloroquine, including Sandoz, Mylan Pharmaceuticals, and Watson Laboratories. The generic medication, which is sold by the name hydroxychloroquine, is only available in a 200 mg strength. PLAQUENIL hydroxychloroquine sulfate tablets is indicated for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, in patients who have not responded satisfactorily to drugs with less potential for serious side effects. Chinese researchers have said chloroquine showed effectiveness inhibiting the new illness in vitro, while French researchers found success using hydroxychloroquine to treat humans with COVID-19.